Physician profile
David Charles Larson
NPI 1356324511
$729.98
in general payments reported to CMS, 2019-2025
15 companies · $232 in 2025
The $232 reported for 2025 was more than what 78% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86.99 · 2021: $53.95 · 2022: $110 · 2023: $127 · 2024: $119 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $479.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $478.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $147.26 | 2022-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Supernus Pharmaceuticals, INC. | $102.38 | 2021-2025 | Qelbree, Qelbree |
| Glaxosmithkline, LLC. | $90.40 | 2019-2025 | Shingrix, Arexvy |
| Viiv Healthcare Company | $66.33 | 2025 | Apretude |
| Cranial Technologies, INC | $50.36 | 2021-2024 | Doc Band |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.45 | 2024-2025 | Stiolto Respimat |
| Sobi, INC | $40.68 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $39.32 | 2019-2023 | Jornay Pm |
| Pfizer INC. | $32.53 | 2023-2025 | |
| Tris Pharma INC | $26.03 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $25.21 | 2024 | Flumist Quadrivalent |
| Mylan Specialty L.P. | $19.20 | 2019 | |
| Azurity Pharmaceuticals, INC. | $17.49 | 2025 | Alvesco |
| Kyowa Kirin, INC. | $16.52 | 2024 | Crysvita |
| Organon LLC | $13.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Larson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.